Two-Year Real-Life Achievements of MiniMed 780G Advanced Closed-Loop System in Youth With Type 1 Diabetes: AWeSoMe Study Group Multicenter Prospective Extended Follow-Up
Authors' conclusion
The 780G Advanced Hybrid Closed-Loop system sustained meaningful glycemic benefits over 2 years, yet most youth failed to achieve optimal composite glycemic control.
Study context
- Population
- Children and adolescents with T1D using the MiniMed 780G system
- Participants
- 96 children
- Outcome
- Glycemic outcomes 12 to 24 months
- Follow-up
- 12 to 24 months
Methodological detailsmulticenter, real-life, extended follow-up, continuous glucose monitoring (CGM) and clinical data at 1, 3, 6, 12 and 24 months; repeated-measures linear mixed models
- Multicenter
- Real-life
- Extended follow-up
- CGM and clinical data at 1, 3, 6, 12 and 24 months; repeated-measures linear mixed models
Main finding
As reported in the abstract
Time below range increased (P = .015)
1.8-2.5%
Observational data: associations, not effects.
Further findings
Composite targets met
- CGC
- 14.6%
- Best GRI
- 9.4%
- Best COGI
- 10.4%
SmartGuard use
- SmartGuard use declined from 91.3% to 82.7% (P = .013)
- Lower socioeconomic position and lower 12-month SmartGuard use were independently associated with the decline
Sex differences
- Girls had lower glycemic variability than boys and greater BMI z-score increase
Safety
- DKA events
- 5
- Severe hypoglycemia events
- 2
- All events device- or behavior-related
Original publication
Two-Year Real-Life Achievements of MiniMed 780G Advanced Closed-Loop System in Youth With Type 1 Diabetes: AWeSoMe Study Group Multicenter Prospective Extended Follow-Up. Endocr Pract. Published 18 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →